U.S. Markets closed

Novartis AG (NVS)

New York Stock Exchange Consolidated Issue - New York Stock Exchange Consolidated Issue Delayed Price. Currency in USD
Add to watchlist
83.28-0.23 (-0.28%)
At close: 4:02PM EDT

82.71 -0.57 (-0.68%)
After hours: 5:40PM EDT

People also watch
GSKSNYAZNLLYABT
Full screen
Previous Close83.51
Open83.11
Bid82.00 x 200
Ask86.00 x 100
Day's Range82.91 - 83.45
52 Week Range66.93 - 86.90
Volume1,114,954
Avg. Volume1,636,912
Market Cap193.18B
Beta0.70
PE Ratio (TTM)31.31
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.72 (3.27%)
Ex-Dividend Date2017-03-01
1y Target EstN/A
Trade prices are not sourced from all markets
  • Are Glaxo's Successful New Drugs Enough to Drive Growth?
    Zacks10 hours ago

    Are Glaxo's Successful New Drugs Enough to Drive Growth?

    Despite the success of new products, GlaxoSmithKline plc (GSK) believes that its overall performance has been weaker than it would have liked.

  • Reuters10 hours ago

    Profit finally in sight for gene therapy specialist Oxford Bio

    After 20 years of losses, gene therapy specialist Oxford BioMedica is at last close to achieving its first profit thanks to the success of Novartis with a pioneering cancer treatment. As manufacturer of the virus-based gene delivery system central to the Novartis therapy, which re-engineers a patient's immune cells to attack cancer, the small British company will receive a modest slice of the revenue once the new drug is approved. The payout will hardly make a dent in returns for Swiss drugs giant Novartis, but the 65-75 million pounds ($83-96 million) a year that Jefferies analysts predict Oxford Bio will earn should put it on a path to sustainable profitability.

  • Market Realist11 hours ago

    Inside Incyte’s Jakafi Performance in 2Q17

    Incyte's Jakafi is the only FDA-approved drug for the treatment of myelofibrosis and polycythemia vera.